Wells Fargo’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.73M | Sell |
115,652
-36,645
| -24% | -$1.69M | ﹤0.01% | 2357 |
|
|
2025
Q4 | $6.83M | Buy |
152,297
+37,076
| +32% | +$1.56M | ﹤0.01% | 2379 |
|
|
2025
Q3 | $4.63M | Buy |
115,221
+2,659
| +2% | +$93.7K | ﹤0.01% | 2647 |
|
|
2025
Q2 | $3.52M | Buy |
112,562
+46,650
| +71% | +$1.52M | ﹤0.01% | 2737 |
|
|
2025
Q1 | $2.21M | Buy |
65,912
+6,392
| +11% | +$243K | ﹤0.01% | 3091 |
|
|
2024
Q4 | $2.33M | Sell |
59,520
-936
| -2% | -$38.7K | ﹤0.01% | 3090 |
|
|
2024
Q3 | $2.38M | Buy |
60,456
+1,389
| +2% | +$56K | ﹤0.01% | 2924 |
|
|
2024
Q2 | $2.3M | Sell |
59,067
-2,390
| -4% | -$95.5K | ﹤0.01% | 2864 |
|
|
2024
Q1 | $2.65M | Buy |
61,457
+3,034
| +5% | +$140K | ﹤0.01% | 2761 |
|
|
2023
Q4 | $2.69M | Sell |
58,423
-1,210
| -2% | -$42.8K | ﹤0.01% | 2666 |
|
|
2023
Q3 | $2.04M | Buy |
59,633
+1,040
| +2% | +$38.9K | ﹤0.01% | 2797 |
|
|
2023
Q2 | $2.26M | Buy |
58,593
+54,647
| +1,385% | +$2.17M | ﹤0.01% | 2808 |
|
|
2023
Q1 | $141K | Buy |
3,946
+2,823
| +251% | +$104K | ﹤0.01% | 4633 |
|
|
2022
Q4 | $44.3K | Buy |
1,123
+623
| +125% | +$22.7K | ﹤0.01% | 4916 |
|
|
2022
Q3 | $18K | Buy |
+500
| New | +$18K | ﹤0.01% | 5459 |
|
|
2020
Q1 | – | Sell |
-300
| Closed | -$4K | – | 6893 |
|
|
2019
Q4 | $4K | Hold |
300
| – | – | ﹤0.01% | 6089 |
|
|
2019
Q3 | $3K | Hold |
300
| – | – | ﹤0.01% | 6156 |
|
|
2019
Q2 | $3K | Hold |
300
| – | – | ﹤0.01% | 6131 |
|
|
2019
Q1 | $3K | Hold |
300
| – | – | ﹤0.01% | 5828 |
|
|
2018
Q4 | $2K | Hold |
300
| – | – | ﹤0.01% | 6218 |
|
|
2018
Q3 | $4K | Sell |
300
-150
| -33% | -$1.74K | ﹤0.01% | 6153 |
|
|
2018
Q2 | $4K | Hold |
450
| – | – | ﹤0.01% | 6116 |
|
|
2018
Q1 | $2K | Sell |
450
-2,014
| -82% | -$7.45K | ﹤0.01% | 6216 |
|
|
2017
Q4 | $7K | Hold |
2,464
| – | – | ﹤0.01% | 6001 |
|
|
2017
Q3 | $7K | Hold |
2,464
| – | – | ﹤0.01% | 5958 |
|
|
2017
Q2 | $8K | Hold |
2,464
| – | – | ﹤0.01% | 5827 |
|
|
2017
Q1 | $10K | Sell |
2,464
-50
| -2% | -$393 | ﹤0.01% | 5882 |
|
|
2016
Q4 | $19K | Buy |
2,514
+50
| +2% | +$402 | ﹤0.01% | 5645 |
|
|
2016
Q3 | $20K | Sell |
2,464
-461
| -16% | -$3.56K | ﹤0.01% | 5598 |
|
|
2016
Q2 | $17K | Sell |
2,925
-2,000
| -41% | -$13.7K | ﹤0.01% | 5533 |
|
|
2016
Q1 | $34K | Buy |
4,925
+361
| +8% | +$2.59K | ﹤0.01% | 5357 |
|
|
2015
Q4 | $37K | Buy |
4,564
+2,300
| +102% | +$19.7K | ﹤0.01% | 5389 |
|
|
2015
Q3 | $19K | Sell |
2,264
-350
| -13% | -$3.48K | ﹤0.01% | 5558 |
|
|
2015
Q2 | $30K | Buy |
2,614
+150
| +6% | +$2.07K | ﹤0.01% | 5476 |
|
|
2015
Q1 | $42K | Sell |
2,464
-4,403
| -64% | -$81.3K | ﹤0.01% | 5090 |
|
|
2014
Q4 | $136K | Buy |
+6,867
| New | +$101K | ﹤0.01% | 4612 |
|
Other funds holding XENE
ACA
DCM
PCH
Wells Fargo's XENE Position: Q1 2026 in Review
Wells Fargo reduced its Xenon Pharmaceuticals (XENE) stake by 24% in Q1 2026, selling an estimated $1.69M and leaving 115,652 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2357.
Wells Fargo first reported a position in XENE in Q4 2014 and has held it in 36 quarters since. The position peaked at $6.83M in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.
- Wells Fargo held 115,652 shares of Xenon Pharmaceuticals worth $6.73M as of Q1 2026.
- Wells Fargo sold 36,645 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.69M.
- Xenon Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2357 holding.
- Wells Fargo first reported a position in Xenon Pharmaceuticals in Q4 2014 and has held it in 36 quarters since.
- Wells Fargo's Xenon Pharmaceuticals position peaked at $6.83M in Q4 2025.
- 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.